3 Stocks Pulling The Drugs Industry Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 41 points (0.2%) at 17,692 as of Thursday, May 5, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,523 issues advancing vs. 1,363 declining with 169 unchanged. The Drugs industry currently sits down 0.9% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Shire ( SHPG), up 0.6%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 4.7%, Alexion Pharmaceuticals ( ALXN), up 1.1%, AbbVie ( ABBV), up 0.9%, Pfizer ( PFE), up 0.9% and Abbott Laboratories ( ABT), up 0.8%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biomarin Pharmaceutical is down $1.40 (-1.7%) to $80.74 on light volume. Thus far, 446,223 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $79.32-$82.63 after having opened the day at $82.20 as compared to the previous trading day's close of $82.14. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $13.8 billion and is part of the health care sector. Shares are down 21.6% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Biomarin Pharmaceutical as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Biomarin Pharmaceutical Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 2. As of noon trading, Mallinckrodt ( MNK) is down $2.07 (-3.3%) to $61.01 on average volume. Thus far, 1.4 million shares of Mallinckrodt exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $59.96-$62.66 after having opened the day at $62.63 as compared to the previous trading day's close of $63.08. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents in the United States, Europe, the Middle East, Africa, and internationally. Mallinckrodt has a market cap of $7.3 billion and is part of the health care sector. Shares are down 15.5% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Mallinckrodt a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Mallinckrodt as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and a generally disappointing performance in the stock itself. Get the full Mallinckrodt Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 1. As of noon trading, Merck ( MRK) is down $0.90 (-1.6%) to $53.91 on average volume. Thus far, 4.7 million shares of Merck exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $53.34-$54.40 after having opened the day at $54.28 as compared to the previous trading day's close of $54.81. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $152.9 billion and is part of the health care sector. Shares are up 3.8% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Merck Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).